Medikinet

Methylphenidate Hydrochloride, the active ingredient in Medikinet, is a central nervous system stimulant presented as oral tablets for oral use. It is prescribed for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults.

GNH USA supplies Medikinet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medikinet is a central nervous system stimulant indicated for specific neurobehavioral disorders.

- Attention Deficit Hyperactivity Disorder (ADHD): improves focus, reduces hyperactivity and impulsivity in patients. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: gastrointestinal discomfort. - Irritability: mood changes and increased agitation. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Seizures: increased risk in susceptible individuals. - Hallucinations: visual or auditory disturbances. - Priapism: prolonged painful erection in males.

Before initiating therapy, evaluate cardiovascular status, psychiatric history, and growth parameters in children. - Cardiovascular assessment: monitor blood pressure and heart rate regularly. - Psychiatric monitoring: watch for emergence of anxiety, aggression, or mood swings. - Growth monitoring: track height and weight in pediatric patients. - Abuse potential: assess risk of misuse or diversion. - Drug interactions: avoid concomitant use with monoamine oxidase inhibitors. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Methylphenidate may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Sympathomimetic agents (e.g., ephedrine): can exacerbate hypertension and tachycardia.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase serotonin levels. - Antihistamines: potential for enhanced sedation. - Antacids: may alter absorption of oral tablets. - Alcohol: can intensify central nervous system effects.